Hongene Expands Phosphoramidite Production Capability to 58(t).
Hongene has expanded its the expansion of its phosphoramidite and nucleotide production capabilities with the launch of operations at its new Manufacturing Facility No. 2 in Shanghai, China.
The new facility has a total space of over 300,000 sq. ft. and covers phosphoramidites and nucleotides production. By combining with the old manufacturing facility, Hongene's total phosphoramidites production capacity is now 58t. For mRNA raw materials, NTP production capacity is up by 36,000L, sufficient to support 7 billion doses of mRNA vaccine.
With this new facility, Hongene is well-positioned to offer unparalleled support from early clinical phases through commercialization in the RNA industry worldwide by providing faster and more reliable solutions.